



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	159395	D3 Capsules
ARTG entry for	Medicine Listed	
Sponsor	FIT-BioCeuticals Limited	
Postal Address	Care of Blackmores Ltd PO Box 1725, Warriewood, NSW, 2102 Australia	
ARTG Start Date	17/02/2009	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . D3 Capsules

Product Type	Single Medicine Product	Effective Date	12/06/2020
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Maintain/support bone health
Aids/assists healthy bone development/growth/building
Maintain/support bone mass/density/integrity
Maintain/support bone strength
Help maintain/support bone mineralisation
Maintain/support healthy cardiovascular system function
Maintain/support healthy immune system function
Maintain/support absorption of dietary (state vitamin/mineral/nutrient)
Maintain/support (state vitamin/mineral/nutrient) levels in the body
Maintain/support nervous system function

Indication Requirements

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis.
Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Product presentation must not imply or refer to serious immunological diseases.

Product presentation must not imply or refer to serious cardiovascular conditions.

Standard Indications

No Standard Indications included on Record

Public Summary



Australian Government
Department of Health
Therapeutic Goods Administration

Specific Indications

No Specific Indications included on Record

Warnings

No Warnings included on Record

Additional Product information**Container information**

Type	Material	Life Time	Temperature	Closure	Conditions
Multiple containers	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison information

Pack Size	Poison Schedule
-----------	-----------------

Components**1 . Formulation 1**

Dosage Form Capsule, soft

Route of Administration Oral

Visual Identification**Active Ingredients**

colecalciferol 25 microgram

Other Ingredients (Excipients)

Gelatin

glycerol

Soya Oil

titanium dioxide

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary